Fueling the FIRES

Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome

Raquel Farias-Moeller, Reghann LaFrance-Corey, Luca Bartolini, Elizabeth M. Wells, Meredith Baker, Alyssa Doslea, William Suslovic, Jay Greenberg, Jessica L. Carpenter, Charles L Howe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection–related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.

Original languageEnglish (US)
Pages (from-to)1753-1763
Number of pages11
JournalEpilepsia
Volume59
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Hemophagocytic Lymphohistiocytosis
Epilepsy
Fever
Infection
Critical Illness
Cerebrospinal Fluid
Chemokine CCL8
Neurocirculatory Asthenia
Neopterin
CXC Chemokines
Interleukin-18
Interleukin-1
Chemokines
Hospitalization
Databases
Cytokines
Phenotype
Serum

Keywords

  • febrile infection–related epilepsy syndrome
  • hemophagocytic lymphohistiocytosis
  • refractory status epilepticus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Farias-Moeller, R., LaFrance-Corey, R., Bartolini, L., Wells, E. M., Baker, M., Doslea, A., ... Howe, C. L. (2018). Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. Epilepsia, 59(9), 1753-1763. https://doi.org/10.1111/epi.14524

Fueling the FIRES : Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. / Farias-Moeller, Raquel; LaFrance-Corey, Reghann; Bartolini, Luca; Wells, Elizabeth M.; Baker, Meredith; Doslea, Alyssa; Suslovic, William; Greenberg, Jay; Carpenter, Jessica L.; Howe, Charles L.

In: Epilepsia, Vol. 59, No. 9, 01.09.2018, p. 1753-1763.

Research output: Contribution to journalArticle

Farias-Moeller, R, LaFrance-Corey, R, Bartolini, L, Wells, EM, Baker, M, Doslea, A, Suslovic, W, Greenberg, J, Carpenter, JL & Howe, CL 2018, 'Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome', Epilepsia, vol. 59, no. 9, pp. 1753-1763. https://doi.org/10.1111/epi.14524
Farias-Moeller R, LaFrance-Corey R, Bartolini L, Wells EM, Baker M, Doslea A et al. Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. Epilepsia. 2018 Sep 1;59(9):1753-1763. https://doi.org/10.1111/epi.14524
Farias-Moeller, Raquel ; LaFrance-Corey, Reghann ; Bartolini, Luca ; Wells, Elizabeth M. ; Baker, Meredith ; Doslea, Alyssa ; Suslovic, William ; Greenberg, Jay ; Carpenter, Jessica L. ; Howe, Charles L. / Fueling the FIRES : Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. In: Epilepsia. 2018 ; Vol. 59, No. 9. pp. 1753-1763.
@article{15a24bce04944bfaad234b1a7b07d863,
title = "Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome",
abstract = "Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection–related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.",
keywords = "febrile infection–related epilepsy syndrome, hemophagocytic lymphohistiocytosis, refractory status epilepticus",
author = "Raquel Farias-Moeller and Reghann LaFrance-Corey and Luca Bartolini and Wells, {Elizabeth M.} and Meredith Baker and Alyssa Doslea and William Suslovic and Jay Greenberg and Carpenter, {Jessica L.} and Howe, {Charles L}",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/epi.14524",
language = "English (US)",
volume = "59",
pages = "1753--1763",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Fueling the FIRES

T2 - Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome

AU - Farias-Moeller, Raquel

AU - LaFrance-Corey, Reghann

AU - Bartolini, Luca

AU - Wells, Elizabeth M.

AU - Baker, Meredith

AU - Doslea, Alyssa

AU - Suslovic, William

AU - Greenberg, Jay

AU - Carpenter, Jessica L.

AU - Howe, Charles L

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection–related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.

AB - Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection–related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities. Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation. Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable. Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.

KW - febrile infection–related epilepsy syndrome

KW - hemophagocytic lymphohistiocytosis

KW - refractory status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=85052600758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052600758&partnerID=8YFLogxK

U2 - 10.1111/epi.14524

DO - 10.1111/epi.14524

M3 - Article

VL - 59

SP - 1753

EP - 1763

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 9

ER -